Treatment of Celiac Disease Confirmed in a Patient Receiving Immune Checkpoint Inhibitors Presenting with Diarrhoea

Patients undergoing treatment with immune checkpoint inhibitors who develop diarrhoea may have underlying coeliac disease. When coeliac serology is obtained and coeliac disease is confirmed in this context, a specific management approach applies.

Clinical Scenario

Coeliac disease confirmed in a patient currently receiving immune checkpoint inhibitors, presenting with diarrhoea or a CeD-like enteropathy. In patients receiving immune checkpoint inhibitors who develop diarrhoea, coeliac serology should be obtained to evaluate for this diagnosis.

Presenting feature: Diarrhoea

First-Line Management Approach

Once coeliac disease is confirmed in this setting, first-line management centres on a specific dietary intervention. The complete structured regimen — including the full protocol steps and supporting evidence — is available via the link below.

Full protocol details, sequencing, and clinical decision support available below.

Instant Access to Structured Evidence-Based Regimens

References

In patients receiving immune checkpoint inhibitors (ICI) who develop diarrhoea, coeliac serology should be obtained.
First‐line management is a strict GFD when CeD is confirmed.

DOI: 10.1002/ueg2.70195

View source ↗